I338 can safely improve glycaemic control in insulin-naive patients with type 2 diabetes with no evidence of a difference compared with insulin glargine, a widely used subcutaneously administered basal insulin (The Lancet Diabetes & Endocrinology)
Diabetes News
Tag: oral insulin
Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial
I338 can safely improve glycaemic control in insulin-naive patients with type 2 diabetes with no evidence of a difference compared with insulin glargine, a widely used subcutaneously administered basal insulin. Further development of this particular oral insulin project was discontinued because I338 doses were high and, therefore, production of the required quantities of I338 for wide public use was deemed not commercially viable. Improvement of technologies involved in the product’s development is the focus of ongoing research
Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis
This systematic review and meta-analysis showed that oral insulin is comparable to SC insulin with regard to glycemic efficacy and safety. However, it is necessary to conduct additional studies in which oral insulin administered to large number of patients for long enough periods of time (Journal of Endocrinological Investigation)
Glycosmedia is also available as an App: